Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Bloating in Cystic Fibrosis
NCT05408910Phase 3Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, triple-blind trial in cystic fibrosis (CF) comparing Rifaximin with Placebo (2 arms). Primary endpoint: Rifaximin Treatment Group Improvement of Symptoms at 2 weeks. Planned start Jul 2025; status: withdrawn.
02
Drugs
rifaximin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05408910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05408910.